


REMARKS

As a result of the forgoing claim amendments, claims 1-18 and 21 have been amended. Claims 19, 20 and 22 have been canceled, and new claim 23 has been added. Claims 1-18, 21 and 23 are now pending. An abstract has also been added.

No new matter has been entered as a result of these amendments. The amendments serve to place the translated claims in proper format for United States practice, to avoid multiple dependencies and add the abstract required for United States practice.

Respectfully submitted,



F. Aaron Dubberley, Reg. No. 41,001
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3737
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0089 US NP